KRRO

Korro BioC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$18.00

Analysis reference price unavailable

Analysis 2026-05-08 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$14.00

Analysis reference price unavailable

Analysis 2026-05-08 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$8.00

Analysis reference price unavailable

Analysis 2026-05-08 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

This remains a cautious post-earnings monitoring setup rather than a clean thesis upgrade. The company-source evidence on May 7, 2026 improved balance-sheet visibility and preserved the Q2 2026 AATD nomination, 2H 2026 KRRO-121 filing, and 2H 2026 third GalNAc-conjugated program nomination milestones, but no trustworthy checked source provided a clear consensus surprise or meaningful T+3 analyst-revision signal. The added long-horizon program catalyst helps round out the milestone map, but it is still preclinical optionality and does not remove the low-coverage, high-uncertainty profile.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-05-31catalystQ1 earnings reset extends runway but looks partly absorbedMedium impact

Korro's May 7, 2026 earnings update reaffirmed cash, cash equivalents and marketable securities of $157.1 million at March 31, 2026 and management said that should fund operations into the second half of 2028, helped by the oversubscribed $85 million private placement; that lowers near-term financing pressure, but the liquidity benefit is likely partly reflected already [#8-K-2026-05-07][#10-Q-2026-05-07].

2026-06-30eventGalNAc AATD development-candidate nomination remains the nearest clean proof pointHigh impact

Management said it is on track to announce a development candidate for the GalNAc-conjugated AATD program in the second quarter of 2026 after reporting greater than 90% in vivo RNA editing, making this the nearest execution checkpoint for whether the post-KRRO-110 pivot is translating into a credible follow-on asset [#8-K-2026-05-07].

2026-10-15eventKRRO-121 regulatory filing in 2H 2026 is still the main value inflectionHigh impact

The company reiterated that KRRO-121 remains on track for a regulatory filing in the second half of 2026 to enable a first-in-human trial, which remains the core asset-specific catalyst because Korro is still pre-revenue and heavily dependent on converting preclinical work into a clinical program [#10-Q-2026-05-07][#8-K-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology